Brief: Nanobiotix Announces Progress In Global Nbtxr3 Development Collaboration Highlighting Robust Pipeline And Pathway To Long-Term Growth
21/05/2024 21:17
May 21 (Reuters) - Nanobiotix SA NANOB.PA :
* REG-NANOBIOTIX ANNOUNCES PROGRESS IN GLOBAL NBTXR3
DEVELOPMENT
COLLABORATION HIGHLIGHTING ROBUST PIPELINE AND PATHWAY TO
LONG-TERM GROWTH
* RECEIVED US FDA "STUDY MAY PROCEED" LETTER FOR A NEW
RANDOMIZED
PHASE 2 STUDY EVALUATING NBTXR3 IN STAGE 3 LUNG CANCER
* NANOBIOTIX IS CURRENTLY VETTING OPTIONS FOR EXTENSION OF
COMPANY'S CASH RUNWAY BEYOND CURRENT EXPECTATION OF 3Q2025.
* PHASE 1 COMPLETED WITH PRIMARY ENDPOINTS MET
Source text for Eikon: ID:nGNEbgplXp
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering